Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes.

Background: The evidence for neoadjuvant targeted therapy in non-small cell lung cancer is limited, with 2 phase 3 trials currently recruiting and no approved indications.

Methods: We describe our experience with the use of neoadjuvant targeted therapy for patients with operable non-small cell lung cancer.

Results: Our focus is on surgical outcomes, which represent an underreported aspect of the patient trajectory.